
ABSTRACT

Compounds of formula (I):



(I)

pharmaceutically acceptable salt thereof, and pharmaceutically acceptable solvates of either entity, wherein X is CH or N; Y is optionally monounsaturated C_3-C_5 alkylene optionally substituted with C_1-C_4 alkyl or methylene; R^1 is H; C_1-C_4 alkyl optionally substituted with C_1-C_4 alkoxy, OH, NR^5R^6, $CONR^5R^6$, C_3-C_6 cycloalkyl or aryl; or C_3-C_6 alkenyl; R^2 is H; C_1-C_4 alkyl optionally substituted with C_1-C_4 alkoxy, OH, NR^5R^6, $CONR^5R^6$, C_3-C_6 cycloalkyl or aryl; or $CONR^5R^6$; R^3 and R^4 are each independently selected from H; C_1-C_4 alkyl optionally substituted with NR^5R^6; C_1-C_4 alkoxy; halo; $CONR^5R^6$ and aryl; R^5 and R^6 are each independently selected from H and C_1-C_4 alkyl; and m and n are each independently 1, 2 or 3; are potent and selective thrombin inhibitors useful in the treatment of, inter alia, deep vein thrombosis; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; restenosis and occlusion following angioplasty; or neurodegenerative disorders.

This Sheet Has Been Replaced

